Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pacific Biosciences ( (PACB) ) has shared an update.
On January 30, 2025, PacBio appointed Christopher M. Smith, CEO of NeoGenomics, to its Board of Directors, leveraging his extensive experience in diagnostics and laboratory testing markets to expand into the clinical genomics market. Concurrently, David Meline resigned from the board, a member since 2023, with no disagreements noted, marking a strategic shift in board composition to strengthen PacBio’s leadership as it continues its innovative journey in sequencing technology.
More about Pacific Biosciences
PacBio, also known as Pacific Biosciences (NASDAQ: PACB), is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions. Their products are grounded in HiFi long-read sequencing and SBB® short-read sequencing technologies, focusing on accuracy, quality, and completeness. These solutions cater to a wide range of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.
YTD Price Performance: -13.33%
Average Trading Volume: 10,536,298
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $440.9M
For detailed information about PACB stock, go to TipRanks’ Stock Analysis page.
